ADVANZ PHARMA Acquires Bayer's Testoviron Commercial Rights in Key Markets
CompanyDeals

ADVANZ PHARMA Acquires Bayer’s Testoviron Commercial Rights in Key Markets

Medtide's IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services
CompanyDeals

Medtide’s IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services

Shanghai Innogen's Diabetes Drug Patent for Efsubaglutide Alfa Fully Invalidated
CompanyDrug

Shanghai Innogen’s Diabetes Drug Patent for Efsubaglutide Alfa Fully Invalidated

Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer's Disease
CompanyDrug

Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer’s Disease

Bayer Wins Beijing MPA Approval for MEDRAD Stellant D-CE Medical Device
CompanyMedical Device

Bayer Wins Beijing MPA Approval for MEDRAD Stellant D-CE Medical Device

Joincare Pharma Gets NMPA Green Light for Pediatric Influenza Drug JKN2301
CompanyDrug

Joincare Pharma Gets NMPA Green Light for Pediatric Influenza Drug JKN2301

Abbott Partners with Abu Dhabi Department of Health to Localize Pharma Production and Digital Health Solutions
CompanyDeals

Abbott Partners with Abu Dhabi Department of Health to Localize Pharma Production and Digital Health Solutions

Sanofi and Abu Dhabi Department of Health Collaborate to Accelerate Vaccine Development
CompanyDeals

Sanofi and Abu Dhabi Department of Health Collaborate to Accelerate Vaccine Development

Platinum Life Biotech's Ruibosheng First Prescribed in China for aGVHD Treatment
CompanyDrug

Platinum Life Biotech’s Ruibosheng First Prescribed in China for aGVHD Treatment

MindRank's MDR-001 Phase IIb Study Achieves Clinical Endpoints for Weight Loss
CompanyDrug

MindRank’s MDR-001 Phase IIb Study Achieves Clinical Endpoints for Weight Loss

Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China
CompanyDrug

Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China

Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma
CompanyDrug

Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma